Biotech Values

[DewDiligence]

>Lessons from ptie: be very cautious of phase III trials based on flimsy phase II's (both oxytrex and the ibs drug). This mad rush to go into phase III can be reckless.<

I would temper that by saying that it depends on how well understood the treatment pathway is. For instance, DNA jumped directly from phase-1/2 to dual pivotal trials for Lucentis because the VEGF pathway was well understood (by them).